Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Van Laar

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Clinical Pharmacokinetics|October 8, 1999
Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's diseaseC Neef, T van Laar
Acta Neurologica Scandinavica|July 28, 2015
Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's diseaseT van Laar, D Nyholm, R Nyman
Journal of Parkinson'S Disease|October 15, 2019
Faecal Transplantation, Pro- and Prebiotics in Parkinson's Disease; Hope or Hype?T Van Laar, J M Boertien, A Horta Herranz
Nederlands Tijdschrift Voor Geneeskunde|April 4, 1992
[Nasolabial allergic reaction to intranasal administration of apomorphine in Parkinson disease]T van Laar, M R Kruyswijk, E N Jansen
Spinal Cord|November 18, 2009
Tolerance to continuous intrathecal baclofen infusion can be reversed by pulsatile bolus infusionH W Heetla, M J Staal, T van Laar
Nederlands Tijdschrift Voor Geneeskunde|July 2, 1994
[Limited value of the apomorphine test in Parkinson disease]R A Roos, T van Laar, J J van Hilten
Tijdschrift Voor Gerontologie En Geriatrie|January 22, 2010
[The possible value of diagnosing MCI-DLB and treatment options]M T Feitsma, T van Laar, P L J Dautzenberg
Current Protein & Peptide Science|October 9, 2002
Mif1: a missing link between the unfolded protein response pathway and ER-associated protein degradation?T van Laar, A J van der Eb, C Terleth
Spinal Cord|April 1, 2009
The incidence and management of tolerance in intrathecal baclofen therapyH W Heetla, M J Staal, C Kliphuis, et al.
BMC Neurology|May 1, 2024
Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutationO Siemeling, S Slingerland, S van der Zee, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Clinical Pharmacokinetics|October 8, 1999
Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's diseaseC Neef, T van Laar
Acta Neurologica Scandinavica|July 28, 2015
Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's diseaseT van Laar, D Nyholm, R Nyman
Journal of Parkinson'S Disease|October 15, 2019
Faecal Transplantation, Pro- and Prebiotics in Parkinson's Disease; Hope or Hype?T Van Laar, J M Boertien, A Horta Herranz
Nederlands Tijdschrift Voor Geneeskunde|April 4, 1992
[Nasolabial allergic reaction to intranasal administration of apomorphine in Parkinson disease]T van Laar, M R Kruyswijk, E N Jansen
Spinal Cord|November 18, 2009
Tolerance to continuous intrathecal baclofen infusion can be reversed by pulsatile bolus infusionH W Heetla, M J Staal, T van Laar
Nederlands Tijdschrift Voor Geneeskunde|July 2, 1994
[Limited value of the apomorphine test in Parkinson disease]R A Roos, T van Laar, J J van Hilten
Tijdschrift Voor Gerontologie En Geriatrie|January 22, 2010
[The possible value of diagnosing MCI-DLB and treatment options]M T Feitsma, T van Laar, P L J Dautzenberg
Current Protein & Peptide Science|October 9, 2002
Mif1: a missing link between the unfolded protein response pathway and ER-associated protein degradation?T van Laar, A J van der Eb, C Terleth
Spinal Cord|April 1, 2009
The incidence and management of tolerance in intrathecal baclofen therapyH W Heetla, M J Staal, C Kliphuis, et al.
BMC Neurology|May 1, 2024
Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutationO Siemeling, S Slingerland, S van der Zee, et al.
Pageof 7